Unsafe
Mostly Unaligned
Patient Risk:
Moderate
Summary
Several timing/vaccine-effectiveness claims are not supported by the provided COSENTYX label excerpts, and some claims introduce external sources (manufacturer guidance, DrugPatentWatch.com) that are not part of the supplied prescribing information.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a monoclonal antibody that targets IL-17A.
Label Mechanism of Action: “Secukinumab… selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.” (12.1)
By blocking IL-17A, Cosentyx helps reduce inflammation.
Mechanism of Action indicates inhibition of IL-17A interaction with IL-17 receptor (12.1). Note: Label excerpt provided does not explicitly use the phrase “reduce inflammation,” but supports IL-17A pathway inhibition.
Cosentyx is used to manage psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Indications: plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis (1 INDICATIONS AND USAGE).
Unsupported Statements
The flu shot contains inactivated influenza viruses.
No immunization/vaccine formulation details for influenza shots are present in the supplied COSENTYX label excerpts.
Novartis’ manufacturer guidance states the flu shot can be administered at any time regardless of when a person is taking Cosentyx.
Provided label excerpts do not state that influenza vaccination timing is unrestricted during COSENTYX treatment; moreover, this refers to manufacturer guidance not included in the supplied prescribing information.
DrugPatentWatch.com states there are no known interactions between secukinumab (Cosentyx) and the flu vaccine.
The supplied label excerpts do not state that there are no interactions between COSENTYX and influenza vaccine. This also relies on an external website not included in the provided label.
The article recommends taking a Cosentyx dose 1–2 weeks before the flu shot.
The supplied label excerpts only state to complete age-appropriate vaccinations prior to initiating therapy and that COSENTYX may alter immune response to live vaccines and to avoid live vaccines; no 1–2 week timing recommendation is provided.
If a person has already received a flu shot, the article states they can take Cosentyx as usual without any adjustments.
No label excerpt supports that COSENTYX dosing can proceed “as usual” after an influenza vaccination without any adjustments or timing considerations.
The article claims taking Cosentyx too close to the flu shot may impact the vaccine’s effectiveness.
The supplied label excerpt does not discuss influenza vaccine effectiveness timing relative to COSENTYX.
The article attributes possible reduced vaccine effectiveness to Cosentyx suppressing the immune system and making it less responsive to the vaccine.
While the label excerpt states COSENTYX may alter immune response to live vaccines (5.7), the provided label excerpts do not provide the specific causal explanation in the claim.
The article states that taking Cosentyx 1–2 weeks before the flu shot allows the immune system to recover and enables an adequate vaccine response.
No such timing-based immune recovery or adequate vaccine response rationale is stated in the supplied label excerpts.
The article states it is unlikely that the timing of Cosentyx will have a significant impact on vaccine effectiveness if Cosentyx was taken after the flu shot.
No label excerpt addresses vaccine effectiveness timing for influenza vaccination relative to COSENTYX dosing.
The article states that Cosentyx can affect the immune system and thus requires correct timing when taking a flu shot.
The label excerpt supports immunization considerations (5.7) but does not state that correct timing with influenza vaccination is required.
The article states the flu shot can be taken at any time while taking Cosentyx.
No label excerpt supports unrestricted “any time” administration of influenza vaccination during COSENTYX treatment.
Contradictions
Important Omissions
Clarification whether the influenza vaccine discussed is a live vaccine versus an inactivated vaccine, since the label excerpt only provides live-vaccine avoidance guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Timing and vaccine-effectiveness claims about influenza vaccination are not supported by the supplied COSENTYX label excerpts; misinformation could lead to inappropriate vaccination timing or misunderstandings about vaccine type (live vs non-live).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Unaligned
Primary Issue
Influenza vaccine timing/effectiveness assertions and claims of “no interactions” are not supported by the provided COSENTYX prescribing information excerpts.
Suggested Improvement
Limit vaccine-related statements to what the label excerpt supports: complete age-appropriate vaccinations prior to initiating therapy and avoid live vaccines during COSENTYX; remove or qualify any specific influenza-shot timing recommendations (e.g., 1–2 weeks) unless present in the supplied prescribing information.